Abstract
T lymphocytes generally fail to recognize human colon carcinomas, suggesting that the tumour is beyond reach of immunotherapy. Bacterial superantigens are the most potent known activators of human T lymphocytes and induce T cell cytotoxicity and cytokine production. In order to develop a T-cell-based therapy for colon cancer, the superantigen staphylococcal enterotoxin A (SEA) was given tumour reactivity by genetic fusion with a Fab fragment of the monoclonal antibody C242 reacting with human colon carcinomas. The C242Fab-SEA fusion protein targeted SEA-reactive T cells against MHC-class-II-negative human colon carcinoma cells in vitro at nanomolar concentrations. Treatment of disseminated human colon carcinomas growing in humanized SCID mice resulted in marked inhibition of tumour growth and the apparent cure of the animals. Therapeutic efficiency was dependent on the tumour specificity of the fusion protein and human T cells. Immunohistochemistry demonstrated massive infiltration of human T cells in C242Fab-SEA-treated tumours. The results merit further evaluation of C242Fab-SEA fusion proteins as immunotherapy in patients suffering from colon carcinoma.
Key words: Superantigens, SCID mice, Colon carcinoma, Therapy
References
- 1.Björk P, Jönsson U, Svedberg H, Larsson K, Lind P, Dillner J, Hedlund G, Dohlsten M, Kalland T. Isolation, partial characterization and molecular cloning of a human colon adenom carcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem. 1993;268:2432. [PubMed] [Google Scholar]
- 2.Chen L, Ashe S, Brady WA, Hellstrom I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte moleuces CD28 and CTLA-4. Cell. 1992;71:1093. doi: 10.1016/s0092-8674(05)80059-5. [DOI] [PubMed] [Google Scholar]
- 3.Dohlsten M, Hedlund G, Lando PA, Trowsdale J, Altmann D, Patarroyo M, Fischer H, Kalland T. Role of the adhesion molecule ICAM-1 (CD54) in staphylococcal enterotoxin mediated cytotoxicity. Eur J Immunol. 1991;21:131. doi: 10.1002/eji.1830210120. [DOI] [PubMed] [Google Scholar]
- 4.Dohlsten M, Hedlund G, Åkerblom E, Lando PA, Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumour agents. Proc Natl Acad Sci USA. 1991;88:9287. doi: 10.1073/pnas.88.20.9287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Dohlsten M, Sundstedt A, Björklund M, Hedlung G, Kalland T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer. 1993;54:482. doi: 10.1002/ijc.2910540321. [DOI] [PubMed] [Google Scholar]
- 6.dohlsten M, Abrahmsén L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Förberg C, Lind P, Kalland T. Monoclonal antibody-superantigen fusion proteins: Tumour-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA. 1994;91:8945. doi: 10.1073/pnas.91.19.8945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Fischer H, Dohlsten M, Andersson U, Hedlund G, Ericsson P-O, Hansson J, Sjögren H-O. Production of TNFα and TNFβ by staphylococcal enterotoxin A activated human T cells. J Immunol. 1990;144:4663. [PubMed] [Google Scholar]
- 8.Lando P, Dohlsten M, Hedlund G, Åkerblom E, Kalland T. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens. Cancer Immunol Immunother. 1993;36:223. doi: 10.1007/BF01740903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Larson LN, Johansson C, Lindholm L, Holmgren H. Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumour cells. Int J Cancer. 1988;42:877. doi: 10.1002/ijc.2910420615. [DOI] [PubMed] [Google Scholar]
- 10.Momburg F, Ziegler A, Harpprecht J, Möller P, Moldenhauer G, Hammerling GJ. Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol. 1989;142:352. [PubMed] [Google Scholar]
- 11.Ochi A, Migita K, Xu J, Siminovitch K. In vivo tumor immunotherapy by a bacterial superantigen. J Immunol. 1993;151:3180. [PubMed] [Google Scholar]
- 12.Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M. Cure of xenografted human tumours by bispecific monoclonal antibodies and human T cells. Science. 1994;264:833. doi: 10.1126/science.8171337. [DOI] [PubMed] [Google Scholar]
- 13.Riethmüller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol. 1992;4:647. doi: 10.1016/0952-7915(92)90041-c. [DOI] [PubMed] [Google Scholar]
- 14.Scherer MT, Ignatowicz L, Winslow G, Kappler J, Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu Rev Cell Biol. 1993;9:101. doi: 10.1146/annurev.cb.09.110193.000533. [DOI] [PubMed] [Google Scholar]
- 15.Torbett BE, Picchio G, Mosier DE. hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol Rev. 1991;124:139. doi: 10.1111/j.1600-065x.1991.tb00620.x. [DOI] [PubMed] [Google Scholar]
- 16.Yoo Y-K, Heo DS, Van Thiel DH, Whiteside TL. Tumorinfiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology. 1990;98:259. [PubMed] [Google Scholar]